Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX) dosed the first meningioma patient with [212Pb]VMT-α-NET in an ongoing Phase 1/2a trial. This new LEMONαDE cohort will assess safety, dosimetry, and preliminary anti-tumor activity in SSTR2-expressing meningiomas, expanding development beyond neuroendocrine tumors and targeting a tumor type with limited treatment options.

AI-generated analysis. Not financial advice.

Positive

• First meningioma patient dosed with [212Pb]VMT-α-NET in Phase 1/2a trial
• New LEMONαDE cohort evaluates safety, dosimetry, and anti-tumor activity in meningioma
• Program extends [212Pb]VMT-α-NET beyond NETs to SSTR2-expressing meningiomas
• Meningiomas represent ~40% of central nervous system tumors in U.S.
• Approximately 20% of meningioma cases are higher-grade (WHO grades 2 and 3)

Negative

• None.

News Market Reaction – CATX

-1.11%

1 alert

-1.11% News Effect

On the day this news was published, CATX declined 1.11%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Meningioma share of CNS tumors: ~40% High-grade meningiomas: 20% Inoperable or recurrent grade 1: 30%

3 metrics

Meningioma share of CNS tumors ~40% Proportion of central nervous system tumors in U.S. diagnosed annually

High-grade meningiomas 20% Approximate share of meningioma cases graded 2 and 3 (WHO 2021)

Inoperable or recurrent grade 1 30% Grade 1 meningioma patients with inoperable or recurrent disease

Market Reality Check

Price: $3.54 Vol: Volume 885,870 vs 20-day ...

low vol

$3.54 Last Close

Volume Volume 885,870 vs 20-day average 1,347,462, indicating below-normal trading activity ahead of this update. low

Technical Shares at 3.595 were trading slightly below the 3.62 200-day moving average before this news.

Peers on Argus

Sector peers in related medical/pharma names showed mixed moves, while momentum ...

3 Down

Sector peers in related medical/pharma names showed mixed moves, while momentum scanner names like BWAY, STIM, and CERS were all down about 3–5%, suggesting broader pressure alongside company-specific clinical news.

Previous Clinical trial Reports

5 past events · Latest: May 18 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 18	Cohorts first patients	Positive	-2.3%	First patients dosed in new cohorts across two Phase 1/2a trials.
Apr 20	Interim trial data	Positive	+8.3%	Updated Phase 1/2a VMT-α-NET data with favorable safety and responses.
Jan 09	Interim trial data	Positive	+1.1%	Updated VMT-α-NET safety and efficacy data across three dose cohorts.
Oct 20	Interim trial data	Positive	-28.9%	ESMO 2025 VMT-α-NET update with detailed response and PFS metrics.
Oct 02	Cohort dose escalation	Positive	+1.8%	First patient dosed in second PSV359 cohort with increased dose level.

Pattern Detected

Clinical trial updates have generally been viewed positively but produced mixed price reactions, with both strong gains and sharp declines following data releases.

Recent Company History

Over the past year, Perspective Therapeutics has repeatedly updated investors on its Phase 1/2a radiopharmaceutical trials, particularly [212Pb]VMT-α-NET and PSV359. Prior clinical releases include multiple interim data sets with favorable safety and objective response rates, as well as first‑patient dosed milestones in new cohorts. Price reactions have ranged from a +8.33% move on strong VMT-α-NET data to a -28.95% drop after another interim update, indicating that even positive‑sounding results can trigger both rallies and sell‑offs.

Historical Comparison

-4.0% avg move · Past clinical-trial updates for CATX saw an average move of -4.03%. Today’s meningioma cohort dosing...

clinical trial

-4.0%

Average Historical Move clinical trial

Past clinical-trial updates for CATX saw an average move of -4.03%. Today’s meningioma cohort dosing extends the pattern of incremental 212Pb program milestones.

Clinical news shows steady progression: repeated interim VMT-α-NET data sets, dose escalations in PSV359 cohorts, and first‑patient dosing in new Phase 1/2a cohorts, now expanding VMT-α-NET into meningioma.

Market Pulse Summary

This announcement adds a new meningioma cohort to Perspective’s ongoing Phase 1/2a study of [212Pb]V...

Analysis

This announcement adds a new meningioma cohort to Perspective’s ongoing Phase 1/2a study of [212Pb]VMT-α-NET, broadening its reach beyond neuroendocrine tumors into another SSTR2-expressing indication with significant unmet need. In recent months, the company has reported multiple interim datasets showing favorable safety and investigator-assessed responses. Key future considerations include the depth of anti-tumor activity in meningioma, durability of responses, and how upcoming 2026 data milestones influence the overall 212Pb radiopharmaceutical strategy.

Key Terms

radiopharmaceutical, dosimetry, alpha-particle, somatostatin receptor subtype 2 (SSTR2), +4 more

8 terms

radiopharmaceutical medical

"a radiopharmaceutical development company pioneering advanced treatments for cancers"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

dosimetry medical

"intended to evaluate the safety, dosimetry, and preliminary anti-tumor activity"

Dosimetry is the measurement and calculation of how much ionizing radiation is absorbed by people, tissues, or devices, similar to a thermostat tracking temperature in different rooms to know where and how much heat is present. Investors should care because accurate dosimetry underpins safety, treatment effectiveness, regulatory approval, and liability for products and services that use radiation—affecting market access, costs, and commercial risk.

alpha-particle medical

"lead-based alpha-particle therapy with [212Pb]VMT-α-NET for meningioma"

An alpha-particle is a small, heavy bundle of two protons and two neutrons emitted by certain radioactive materials; think of it like a tiny, dense cannonball of radiation. For investors, its presence matters because alpha emitters are used in some medical treatments and diagnostics and trigger strict safety, handling and disposal rules that affect regulatory approval, manufacturing costs, liability and market acceptance of related products.

somatostatin receptor subtype 2 (SSTR2) medical

"across somatostatin receptor subtype 2 (SSTR2)-expressing tumor types"

Somatostatin receptor subtype 2 (sstr2) is a specific protein found on certain cells that helps regulate hormone signals in the body. Its activity can influence the growth of some tumors and other health conditions, making it a target for specialized medical treatments. For investors, developments involving sstr2 can impact the performance of biotech companies working on related therapies.

neuroendocrine tumors medical

"beyond neuroendocrine tumors (NETs). Meningiomas are the most common"

Neuroendocrine tumors are a type of abnormal growth that originates from cells responsible for releasing hormones into the bloodstream. These tumors can develop in various parts of the body and sometimes grow slowly or remain hidden for years. Their potential to affect hormone levels and spread makes them important for investors to monitor, especially as advancements in treatment may influence healthcare company performance.

World Health Organization (WHO) medical

"are grades 2 and 3 by World Health Organization (WHO) 2021 grading"

The World Health Organization (WHO) is the United Nations agency that coordinates international public health guidance, disease surveillance, and response efforts across countries. Investors watch WHO announcements because its guidance and alerts — similar to a global health traffic controller directing where resources and restrictions should move — can change government policies, travel and trade flows, pharmaceutical demand, and market sentiment, all of which can affect company revenues and stock prices.

meningiomas medical

"Meningiomas are the most common primary brain tumors in adults"

Meningiomas are tumors that grow on the thin protective layers surrounding the brain and spinal cord; many grow slowly but can press on nearby tissue and cause headaches, vision or movement problems. Like a stubborn patch on a wrapped gift that deforms the contents, they matter to investors because their diagnosis, monitoring and treatment drive demand for imaging, surgery, radiotherapy, drugs and ongoing care—areas affected by clinical trial results, approvals and reimbursement decisions.

central nervous system medical

"of all central nervous system tumors diagnosed annually in the United States"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first meningioma patient was dosed with [²¹²Pb]VMT-α-NET in the Company’s ongoing Phase 1/2a study.

The new cohort is intended to evaluate the safety, dosimetry, and preliminary anti-tumor activity of lead-based alpha-particle therapy with [²¹²Pb]VMT-α-NET for meningioma (LEMONαDE). The initiation of the meningioma cohort reflects The Company’s broader strategy to evaluate [²¹²Pb]VMT-α-NET across somatostatin receptor subtype 2 (SSTR2)-expressing tumor types beyond neuroendocrine tumors (NETs).

Meningiomas are the most common primary brain tumors in adults, accounting for ~40% of all central nervous system tumors diagnosed annually in the United States¹. Approximately 20% of all diagnosed meningioma cases are grades 2 and 3 by World Health Organization (WHO) 2021 grading,² while approximately 30% of patients with diagnosed grade 1 disease either have inoperable disease or experience recurrence of their disease.³ Although surgery and radiation remain standard treatments, patients with recurrent, progressive, or unresectable disease often face limited therapeutic options and poor long-term outcomes.² Meningiomas consistently express SSTR2⁴, making them an attractive target for targeted radiopharmaceutical therapy.

About [²¹²Pb]VMT-α-NET
Perspective designed [²¹²Pb]VMT-α-NET to target and deliver ²¹²Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim analysis with a data cut-off date of April 17, 2026 was recently reported at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026, including efficacy data on half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 are pending, and submissions for presentations at additional medical conferences during 2026 are planned.

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

¹ Price M, Ballard CAP, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022. Neuro Oncol. 2025;27(Supplement_4):iv1-iv66. doi:10.1093/neuonc/noaf194
² Wang JZ, Landry AP, Raleigh DR, et al. Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol. 2024;26(10):1742-1780. doi:10.1093/neuonc/noae082
³ Han T, Liu X, Zhou J. Progression/Recurrence of Meningioma: An Imaging Review Based on Magnetic Resonance Imaging. World Neurosurg. 2024;186:98-107. doi:10.1016/j.wneu.2024.03.051
⁴ Agopiantz M, Carnot M, Denis C, Martin E, Gauchotte G. Hormone Receptor Expression in Meningiomas: A Systematic Review. Cancers (Basel). 2023;15(3):980. Published 2023 Feb 3. doi:10.3390/cancers15030980

FAQ

What did Perspective Therapeutics (CATX) announce about its meningioma trial on June 3, 2026?

Perspective Therapeutics announced dosing of the first meningioma patient with [212Pb]VMT-α-NET in its Phase 1/2a LEMONαDE study. According to Perspective Therapeutics, this cohort will assess safety, dosimetry, and preliminary anti-tumor activity in SSTR2-expressing meningiomas.

What is the goal of the Phase 1/2a LEMONαDE study for CATX?

The LEMONαDE study aims to evaluate safety, dosimetry, and preliminary anti-tumor activity of [212Pb]VMT-α-NET in meningioma patients. According to Perspective Therapeutics, this cohort targets SSTR2-expressing tumors and expands development beyond neuroendocrine tumors.

How does the new meningioma cohort expand Perspective Therapeutics’ focus areas (CATX)?

The new cohort broadens use of [212Pb]VMT-α-NET from neuroendocrine tumors to SSTR2-expressing meningiomas. According to Perspective Therapeutics, this supports a strategy to evaluate the therapy across multiple SSTR2-positive tumor types.

Why are meningiomas a significant target for Perspective Therapeutics’ [212Pb]VMT-α-NET?

Meningiomas account for about 40% of central nervous system tumors in U.S. adults. According to Perspective Therapeutics, they consistently express SSTR2, making them attractive for targeted radiopharmaceutical therapy with [212Pb]VMT-α-NET.

What unmet need in meningioma treatment is CATX addressing with [212Pb]VMT-α-NET?

Perspective Therapeutics is targeting patients with recurrent, progressive, or unresectable meningiomas who have limited options beyond surgery and radiation. According to Perspective Therapeutics, these patients often experience poor long-term outcomes, highlighting the need for new targeted therapies.

How common are higher-grade meningiomas in the population addressed by CATX’s trial?

Approximately 20% of diagnosed meningioma cases are WHO 2021 grades 2 and 3. According to Perspective Therapeutics, about 30% of grade 1 patients also have inoperable or recurrent disease, underscoring the potential relevance of new treatments like [212Pb]VMT-α-NET.